Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
- 8 June 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 74 (23), 1860-1867
- https://doi.org/10.1212/wnl.0b013e3181e24373
Abstract
Objective: B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relapsing MS with breakthrough disease defined by clinical and MRI activity (Class III evidence). Methods: Thirty subjects with a relapse within the past 18 months despite use of an injectable disease-modifying agent, and with at least 1 gadolinium-enhancing (GdE) lesion on any of 3 pretreatment MRIs, received rituximab administered at 375 mg/m2 weekly × 4 doses. Three monthly posttreatment brain MRI scans were obtained beginning 12 weeks after the first infusion. Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) were obtained at baseline and throughout the posttreatment follow-up. Results: GdE lesions were reduced after treatment with rituximab, with 74% of posttreatment MRI scans being free of GdE activity compared with 26% free of GdE activity at baseline (p < 0.0001). Median GdE lesions were reduced from 1.0 to 0, and mean number was reduced from 2.81 per month to 0.33 after treatment (88% reduction). MSFC improved as well (p = 0.02). EDSS remained stable. Conclusion: Rituximab add-on therapy was effective based upon blinded radiologic endpoints in this phase II study. In combination with standard injectable therapies, rituximab was well-tolerated with no serious adverse events. B-cell–modulating therapy remains a potential option for treatment of patients with relapsing MS with an inadequate response to standard injectable therapies. Classification of evidence: This study provides Class III evidence that add-on rituximab reduces gadolinium-enhancing brain lesions in multiple sclerosis.Keywords
This publication has 32 references indexed in Scilit:
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 2008
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history studyMultiple Sclerosis Journal, 2000
- Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosisAnnals of Neurology, 1996
- Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trialsAnnals of Neurology, 1994
- Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.The Journal of Experimental Medicine, 1984
- Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdownAnnals of Neurology, 1981